Drug intelligence / Profile preview

docetaxel + indoximod

Development stage: Unknown
Lead developer: Lumos Pharma
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Docetaxel + indoximod is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and indoximod, an oral immunomodulator that inhibits the indoleamine 2,3-dioxygenase (IDO) pathway. IDO is an enzyme that tumors use to create a state of immunosuppression. Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in mouse models of breast cancer. The combination aims to enhance anti-tumor effects through complementary mechanisms of action - docetaxel's cytotoxic effects on cancer cells and indoximod's restoration of immune function against cancer cells.

Targets

IDO1 (Indoleamine 2,3-dioxygenase 1)Microtubule

Beyond the preview

Go deeper on docetaxel + indoximod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + indoximod.

Explore the full profile